Functional Neurosurgery · Trainee Resources

Percutaneous Procedures for Trigeminal Neuralgia

Radiofrequency, Balloon Compression, and Glycerol

A practical guide to the three percutaneous ablative options for trigeminal neuralgia, situated against microvascular decompression and radiosurgery, and organized around the two variables that drive the choice: which divisions are involved, and whether the patient can cooperate awake.

Timoteo Almeida, MD, PhD | Department of Neurological Surgery

Orientation

Classic trigeminal neuralgia — the lancinating, electric, trigger-evoked facial pain of a patient whose MRI shows a vascular loop on the nerve — is one of the few facial pain syndromes that responds reliably to surgery. Our first task is to be sure the diagnosis is actually classic TN and not trigeminal neuropathic or atypical facial pain, because the procedures below work for the former and disappoint for the latter. Once the diagnosis is secure and medical therapy has failed or become intolerable, the patient faces a branching set of options: the durable but more invasive microvascular decompression, the noninvasive but delayed radiosurgery, and the three percutaneous procedures that are the subject of this reading.

The percutaneous procedures all work the same way in principle — a needle through the foramen ovale into Meckel's cave, and a controlled injury to the trigeminal ganglion or rootlets — but they differ in how the injury is produced and, crucially, in what they demand of the patient during the operation. That difference is what makes the choice between them a clinical decision rather than a matter of habit. The framework here turns on two questions: which trigeminal divisions need to be treated, and whether the patient can cooperate with awake testing.

Part I

Where Percutaneous Procedures Sit

1.The Whole Decision Tree

Before choosing among the percutaneous options, it helps to see where they fit. For the medically refractory patient, three broad paths exist. Microvascular decompression (MVD) is the only non-destructive option and the only one that treats the presumed cause — neurovascular conflict — rather than the symptom; it offers the most durable relief and preserves facial sensation, at the cost of a posterior fossa craniotomy and its risks. It is generally favored in younger, healthier patients with imaging-confirmed vascular conflict. Stereotactic radiosurgery is the least invasive, requires no needle and no anesthesia, and suits the patient who cannot or will not undergo an invasive procedure — but its effect is delayed by weeks to months and it, usually, provides no immediate relief. Percutaneous procedures occupy the middle ground: minimally invasive, immediately effective, repeatable, and ideal for older or frailer patients, for those with limited life expectancy, and for medically complex patients in whom a craniotomy is unattractive.

The percutaneous niche Reach for a percutaneous procedure when the patient needs immediate relief, is older or medically fragile, has failed or declined MVD, or has TN secondary to multiple sclerosis (in whom there is no vascular conflict to decompress). All three percutaneous techniques are repeatable if pain recurs.

2.The Common Approach and a Shared Trade-off

All three percutaneous procedures share the transforamen-ovale approach to Meckel's cave, classically via the anatomical landmarks described by Hartel, with fluoroscopic or CT guidance. And all three share a fundamental trade-off that should be stated plainly to every patient: relief is bought with sensory loss. These are deliberately destructive procedures; some degree of facial numbness is expected, and the art lies in producing enough sensory change to stop the pain without producing the dreaded complications of dense numbness — troublesome dysesthesia, anesthesia dolorosa, or, when the first division is involved, corneal anesthesia leading to neurotrophic keratitis. How each technique distributes that risk across the trigeminal divisions is exactly what determines which one to choose.

Part II

The Three Techniques

3.Radiofrequency Thermocoagulation

Radiofrequency (RF) rhizotomy is the most selective of the three. After the electrode is placed through the foramen ovale, the awake patient is used to map the target: low-voltage stimulation evokes paresthesias that the patient localizes to a specific division, allowing the electrode to be positioned precisely in the V2 or V3 territory before any lesion is made. Graded thermal lesions are then created and titrated against the developing sensory change. This awake, division-by-division targeting is RF's defining strength — it can concentrate the lesion on exactly the painful division and largely spare the others.

How the lesion is made and confirmed Step 1 — Stimulation (awake), to confirm position. Sensory stimulation at 50 Hz, pulse width 0.1–1 ms, is delivered while the amplitude is raised slowly from a low level; the patient reports the moment they first feel tingling or discomfort and localizes it, confirming the active tip lies in the trigeminal division that matches the pain (concordant paresthesia at a low threshold, often around 0.1–0.3 V, indicates good placement). Motor stimulation at 2 Hz is used to gauge proximity to the motor root, watching for masseter contraction.

Step 2 — Lesion. Once localization is confirmed, the patient is sedated with a short bolus of propofol, the generator is switched to the radiofrequency thermocoagulation mode, and temperature and time are set — typically 60–75 °C for about 60–90 s, repeated and titrated to the desired sensory change. Relaxation of the masseter, often visible before the lesion time is complete, is a useful sign that anesthesia of the territory has been achieved. Lesions are graded to produce hypalgesia, not dense anesthesia, in the painful division — enough to stop the pain while limiting the risk of anesthesia dolorosa.

That selectivity is also why RF is the preferred percutaneous option for V2 and V3 pain in a cooperative patient. The flip side is the requirement the technique imposes: the patient must be repeatedly woken and able to give reliable sensory feedback during the procedure, alternating with the brief deep sedation needed for the painful lesioning itself. A patient who cannot cooperate — through dementia, anxiety, or medical fragility — cannot be mapped this way, which is the central limitation. RF also carries the most division-specific risk to the cornea: precisely because it can be aimed at V1, an over-extensive or mistargeted V1 lesion risks corneal anesthesia and keratitis.

Practice preference RF thermocoagulation is favored for V2–V3 distribution pain in a cooperative patient, where its awake, selective targeting concentrates the lesion on the painful division and spares the rest of the face.

4.Balloon Compression

Percutaneous balloon compression takes the opposite approach to the patient. A Fogarty catheter is passed through the foramen ovale into Meckel's cave and its balloon is inflated, mechanically compressing the trigeminal ganglion; the classic fluoroscopic sign of correct placement is a "pear-shaped" balloon. The entire procedure is done under brief general anesthesia and requires no awake feedback — which is precisely its advantage for the patient who cannot cooperate with awake mapping.

Balloon compression has two further features that shape its use. First, it preferentially injures the large myelinated fibers that mediate the trigeminal afferent limb, and it is the procedure classically associated with transient masseter weakness from injury to motor fibers — worth counseling, usually temporary. Second, and clinically important, balloon compression has a distinctive relationship to the corneal reflex: it tends to be relatively sparing of the fine fibers, and it is the technique often preferred when the first division (V1) is involved, because the risk of the keratitis-producing corneal anesthesia that haunts V1 RF lesions is believed to be lower. The combination — works asleep, gentler on the cornea — makes balloon compression the natural choice for V1 pain and for the uncooperative or frail patient.

Practice preference Balloon compression is favored when the first division (V1) is involved, or when the patient cannot cooperate with awake testing — it is performed under brief general anesthesia and is comparatively kinder to the corneal reflex.

5.Glycerol Rhizolysis

Glycerol rhizolysis completes the trio. A needle is placed into the trigeminal cistern and glycerol, a mild neurolytic, is injected to chemically injure the rootlets. It sits between the other two in its demands: it does not require the moment-to-moment awake mapping of RF, but it offers less precise control over which divisions are affected and over lesion size. Its principal liabilities are a comparatively higher recurrence rate and the inherent unpredictability of a chemical lesion that spreads according to CSF dynamics rather than electrode position. It remains a reasonable option in selected hands, but in most contemporary practice the choice reduces to RF versus balloon, decided by the two questions of division and cooperation.

6.Putting the Three Side by Side

The three percutaneous procedures compared. Outcome figures are approximate and drawn from long-term series; final technique choice is individualized to the patient.
	Radiofrequency	Balloon compression	Glycerol
Anesthesia	Awake mapping + brief sedation for lesioning	Brief general anesthesia	Sedation; brief awake portions
Targeting	Selective, division-specific (awake stimulation)	Non-selective ganglion compression	Less precise; CSF-dependent spread
Best-fit division	V2–V3, cooperative patient	V1 involvement; any, asleep	Variable
Signature risk	Corneal anesthesia if V1 targeted; dysesthesia	Transient masseter weakness	Higher recurrence; unpredictable lesion
Cooperation needed	Yes — reliable awake feedback	No	Minimal

Part III

Outcomes, Counseling, and the Recurrent Patient

7.What to Expect

All percutaneous procedures share a broadly similar outcome signature: very high rates of immediate pain relief, with gradual recurrence over years as the nerve recovers. Long-term radiofrequency series report initial relief in the high-90s percent, with roughly half to two-thirds of single-procedure patients still pain-free at five years; balloon compression series report comparable initial control with recurrence accruing over a similar horizon. The honest counseling points are three: relief is usually immediate, some facial numbness is expected and is the price of relief, and recurrence is common over years but the procedure can be repeated. Set against MVD — more durable but a craniotomy — and radiosurgery — least invasive but delayed — the percutaneous procedures are the right answer for a specific and recognizable patient, not a default for everyone.

Diagnosis first, always The most consequential errors in facial-pain surgery are made before the patient reaches the operating room. These procedures work for classic, paroxysmal trigeminal neuralgia. They are far less reliable — and can worsen — trigeminal neuropathic pain, anesthesia dolorosa, and atypical facial pain, where adding sensory loss to an already deafferented system is the wrong move. Confirm the phenotype before offering an ablative procedure.

8.The Recurrent, MS, and Postherpetic Patient

Three scenarios deserve specific mention. The patient with TN secondary to multiple sclerosis has a central demyelinating lesion rather than a peripheral vascular conflict, so MVD has little to offer; percutaneous procedures (and radiosurgery) are the mainstays, with the understanding that MS-related TN tends to recur more readily. The patient with recurrence after a prior procedure is well served by the repeatability of the percutaneous options — a second RF or balloon procedure is straightforward, and the choice can be revisited using the same two questions about division and cooperation that guided the first.

Bilateral disease: stage the procedures, never both sides at once Bilateral trigeminal neuralgia — most often in multiple sclerosis — should be treated one side at a time. The hazard is functional rather than vascular: bilateral V3 lesioning risks bilateral masticatory weakness, and bilateral sensory loss can compromise chewing and swallowing. A conservative practice is to lesion one side and then wait until that side has recovered functional use — the patient is chewing and swallowing normally on the treated side — before lesioning the contralateral side. Staging this way ensures the patient is never left with simultaneous bilateral masticatory or swallowing dysfunction, and the first side's sensory result can guide how conservatively to lesion the second.

The postherpetic patient is the important cautionary case. Postherpetic trigeminal pain is deafferentation pain, not classic TN, and it responds far less reliably to the percutaneous ganglion-level procedures — adding sensory loss to an already deafferented nerve is unlikely to help and may worsen the picture. When an ablative approach is warranted in this group, trigeminal tractotomy–nucleotomy — a more invasive lesion of the descending trigeminal tract and nucleus caudalis in the medulla — is the more effective option, and is covered in the companion article on neuropathic and atypical facial pain. The percutaneous ganglion procedures should not be expected to carry postherpetic pain the way they carry classic TN.

9.Postoperative Assessment and Counseling

The postoperative examination is brief but non-negotiable, and it should be documented every time. Test and record facial sensation in each trigeminal division immediately after the procedure: the degree of sensory change is both the marker that an adequate lesion was made and the best available predictor of how durable the relief will be. The relationship is direct — lesions that leave only mild numbness tend to recur quickly, whereas those producing more substantial hypalgesia (on the order of half the normal sensation or more in the treated division) are associated with longer-lasting pain relief. This is the practical tension at the heart of the operation: more sensory loss buys more durable relief but trades against the comfort of a normal-feeling face, and it must be balanced against the risk of dense anesthesia and anesthesia dolorosa.

Corneal sensation must always be checked, especially whenever V1 may have been affected, because a hypesthetic or anesthetic cornea cannot protect itself and is at risk for neurotrophic keratitis. Counsel the patient on eye protection — lubrication, monitoring for redness or irritation, and prompt ophthalmology referral if there is any corneal compromise — and arrange local eye care as needed. A patient who leaves with an unrecognized insensate cornea is the avoidable disaster of this operation.

Part IV

Pearls

Confirm classic, paroxysmal TN before offering any ablative procedure — neuropathic and atypical facial pain respond poorly and can worsen with added sensory loss.
Two questions decide the percutaneous technique: which divisions are involved, and can the patient cooperate awake?
RF thermocoagulation for V2–V3 in a cooperative patient — awake stimulation lets you target the painful division selectively and spare the rest.
Balloon compression for V1 involvement or the uncooperative/frail patient — done under brief general anesthesia, comparatively sparing of the corneal reflex; counsel about transient masseter weakness.
The cornea is the V1 danger: an over-extensive V1 RF lesion risks corneal anesthesia and neurotrophic keratitis — a major reason to favor balloon when V1 is the target.
Glycerol is the middle option — less awake demand than RF, but less precise and with higher recurrence.
All three are minimally invasive, immediately effective, and repeatable — the percutaneous niche is the older, frailer, or medically complex patient and the post-MVD recurrence.
For TN secondary to MS there is no vascular conflict to decompress — percutaneous procedures and radiosurgery are the mainstays.
Postherpetic facial pain is deafferentation pain, not classic TN — it responds poorly to ganglion-level percutaneous procedures; trigeminal tractotomy–nucleotomy is the more effective (more invasive) option.
Confirm the lesion in the awake patient by stimulation: raise the energy until the patient reports tingling and localizes it to the painful division, then sedate and lesion at ~60–75 °C; masseter relaxation signals an adequate lesion.
Aim for hypalgesia, not dense anesthesia — more sensory loss predicts more durable relief but trades against comfort and the risk of anesthesia dolorosa.
Always document post-op facial sensation by division, and always check corneal sensation — an insensate cornea needs eye-protection counseling and ophthalmology follow-up to prevent neurotrophic keratitis.
Counsel every patient on the shared trade-off: relief is bought with some facial numbness, and recurrence over years is common but treatable by repeating the procedure.

Selected References

Kanpolat Y, Savas A, Bekar A, Berk C. Percutaneous controlled radiofrequency trigeminal rhizotomy for the treatment of idiopathic trigeminal neuralgia: 25-year experience with 1,600 patients. Neurosurgery. 2001;48(3):524–534. The definitive long-term RF series.
Mullan S, Lichtor T. Percutaneous microcompression of the trigeminal ganglion for trigeminal neuralgia. J Neurosurg. 1983;59(6):1007–1012. The founding description of balloon compression.
Brown JA, Pilitsis JG. Percutaneous balloon compression for the treatment of trigeminal neuralgia: results in 56 patients based on balloon compression pressure monitoring. Neurosurg Focus. 2005;18(5):E10. Modern technical refinement of balloon compression.
Hakanson S. Trigeminal neuralgia treated by the injection of glycerol into the trigeminal cistern. Neurosurgery. 1981;9(6):638–646. The original glycerol rhizolysis report.
Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019;26(6):831–849. Contemporary diagnostic classification and treatment framework.
Tatli M, Satici O, Kanpolat Y, Sindou M. Various surgical modalities for trigeminal neuralgia: literature study of respective long-term outcomes. Acta Neurochir (Wien). 2008;150(3):243–255. Comparative long-term outcomes across procedures.
Tang YZ, Wu BS, Yang LQ, et al. The management of bilateral trigeminal neuralgia with trigeminal radiofrequency rhizotomy: a treatment strategy for the life-long disease. Acta Neurochir (Wien). 2012;154(9):1639–1645. Staged, sequential strategy for bilateral disease.